SANOFI-AVENTIS (EPA:SAN)

PRESS RELEASE

published on 09/23/2025 at 07:00, 10 months 10 days ago

Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
Sanofi's SAR446268 granted US fast track designation for non-congenital myotonic dystrophy type 1. AAV gene therapy aims to silence DMPK expression, addressing symptoms and filling unmet need

AAV Gene Therapy Sanofi Fast Track Designation SAR446268 Myotonic Dystrophy Type 1
BRIEF

published on 09/17/2025 at 07:05, 10 months 16 days ago

Sanofi's Brivekimig Shows Promise in Hidradenitis Suppurativa Treatment

Brivekimig Hidradenitis Suppurativa Phase 2a Study Nanobody Technology Immune-mediated Diseases
PRESS RELEASE

published on 09/17/2025 at 07:00, 10 months 16 days ago

Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
Sanofi's brivekimig shows positive results in phase 2a study for hidradenitis suppurativa, presenting clinically meaningful improvements in primary and secondary endpoints in biologic-naïve patients

Sanofi Brivekimig Hidradenitis Suppurativa Phase 2a Study Immune-mediated Diseases
PRESS RELEASE

published on 09/15/2025 at 18:30, 10 months 17 days ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 09/12/2025 at 18:35, 10 months 20 days ago

Sanofi Publishes Voting Rights Data for August 2025

Voting Rights Actions Financial Markets Sanofi August 2025
PRESS RELEASE

published on 09/12/2025 at 18:30, 10 months 20 days ago

Sanofi: Information concerning the total number of voting rights and shares - August 2025
Sanofi discloses total number of voting rights and shares as per French regulations. Details available on Sanofi's website

Voting Rights Shares French Regulations Disclosure Sanofi
BRIEF

published on 09/11/2025 at 07:05, 10 months 22 days ago

Sanofi Obtains Fast Track Designation for SAR402663 in the United States

FDA Gene Therapy Sanofi Fast Track AMD
BRIEF

published on 08/29/2025 at 23:55, 11 months 4 days ago

Sanofi’s Wayrilz Gets FDA Approval as First BTK Inhibitor for ITP

FDA Approval Sanofi BTK Inhibitor Wayrilz Immune Thrombocytopenia
PRESS RELEASE

published on 08/29/2025 at 23:50, 11 months 4 days ago

Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia. Novel treatment targets BTK through multi-immune modulation to address root causes of ITP, providing rapid and durable platelet response and improved symptoms

Sanofi BTK Inhibitor Wayrilz Immune Thrombocytopenia LUNA 3 Study
PRESS RELEASE

published on 08/25/2025 at 18:30, 11 months 8 days ago

Sanofi: Disclosure of trading in own shares

Published on 08/01/2026 at 01:20, 2 days 14 hours ago

Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 2 days 14 hours ago

Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 2 days 14 hours ago

Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 08/01/2026 at 00:25, 2 days 15 hours ago

BioNxt Solutions Announces Option Grants
Published on 07/31/2026 at 23:20, 2 days 16 hours ago

Pentagon I Capital Corp. Announces Conditional Acceptance of Qualifying Transaction with Prospectiva Resources Ltd.

View all ACCESSWIRE

Published on 08/03/2026 at 15:18, 7 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Senior plc
Published on 08/03/2026 at 15:17, 8 minutes ago

Form 8.3 - The Vanguard Group, Inc.: SEGRO plc
Published on 08/03/2026 at 15:16, 9 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 08/03/2026 at 15:15, 10 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Rotork plc
Published on 08/03/2026 at 15:14, 11 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.

View all EQS

Published on 08/03/2026 at 10:58, 4 hours 27 minutes ago

GUILLEMOT CORPORATION| Weekly report share buyback from July 27 to July 31 2026
Published on 08/03/2026 at 08:29, 6 hours 57 minutes ago

Launch of a €225 million tranche of its share buyback programme
Published on 08/03/2026 at 07:00, 8 hours 26 minutes ago

BIOPHYTIS PROVIDES AN UPDATE AND SHARE STRATEGIC DRIVERS SUPPORTING ITS HONG KONG JOINT VENTURE
Published on 07/31/2026 at 21:00, 2 days 18 hours ago

Carrefour completes the sale of its minority stake in CarrefourSA in Turkey to Yeni Mağazacılık A.Ş., operator of the A101 retail chain and controlled by the Aydın Group
Published on 07/31/2026 at 19:27, 2 days 19 hours ago

Share retention commitments (Dutreil Agreement)

View all LES ECHOS COMFI WIRE

News